Elevate your local knowledge
Sign up for the iNFOnews newsletter today!
TRENTON, N.J. – Biotech drugmaker Amgen Inc. says its third-quarter profit jumped 24 per cent and beat analysts’ expectations as sales of more than a half-dozen of its drugs increased by double digits.
Amgen, which sells arthritis treatment Enbrel and Prolia for osteoporosis, says net income was $1.37 billion, or $1.79 per share, up from $1.11 billion, or $1.41 per share, a year earlier.
The Thousand Oaks, Calif.-based company says earnings were $1.94 per share excluding one-time items. Analysts were expecting $1.76 per share.
Revenue was up 10 per cent at $4.75 billion. Analysts expected $4.6 billion.
The company also raised the lower end of its 2013 profit forecast by a nickel and now expects $7.35 to $7.45 per share.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Want to share your thoughts, add context, or connect with others in your community?
You must be logged in to post a comment.